Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2C
The experimentally established mechanism targets of Tetrahydrozoline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A known ✓ | P35348 | 4/20 | 0.97 |
| ▸ | ADRA2A known ✓ | P08913 | 3/20 | 0.97 |
| ▸ | ADRA1D known ✓ | P25100 | 1/20 | 0.52 |
| ▸ | ADRA1B known ✓ | P35368 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.97 |
| ▸ | HTR1A | P08908 | 1/20 | 0.97 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.97 |
| ▸ | MEN1 | O00255 | 2/20 | 0.94 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.94 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.94 |
| ▸ | BLM | P54132 | 1/20 | 0.94 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.94 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tetrahydrozoline SCHEMBL29603648 | 0.98 | ADRA2A (1.00) | ADRA1AADRA2ACYP2D6HTR1AOPRM1 | |
| Tetrahydrozoline SCHEMBL34760 | 0.98 | ADRA2A (1.00) | ADRA1AADRA2ACYP2D6HTR1AOPRM1 | |
| Tetrahydrozoline SCHEMBL30292036 | 0.98 | ADRA2A (1.00) | ADRA1AADRA2ACYP2D6HTR1AOPRM1 | |
| Tetrahydrozoline SCHEMBL29393067 | 0.97 | CYP2D6 (1.00) | ADRA1AADRA2ACYP2D6HTR1AOPRM1 | |
| Tetrahydrozoline SCHEMBL25702 | 0.97 | CYP2D6 (1.00) | ADRA1AADRA2ACYP2D6HTR1AOPRM1 | |
| Tetrahydrozoline SCHEMBL23496614 | 0.97 | CYP2D6 (1.00) | ADRA1AADRA2ACYP2D6HTR1AOPRM1 | |
| Tetrahydrozoline SCHEMBL9296922 | 0.96 | CYP2D6 (0.97) | ADRA1AADRA2ACYP2D6HTR1AOPRM1 | |
| Tetrahydrozoline SCHEMBL1140101 | 0.91 | ADRA1A (0.85) | ADRA1AADRA2ACYP2D6HTR1AOPRM1 | |
| SCHEMBL10930958 | 0.89 | CYP2D6 (0.83) | ADRA1AADRA2ACYP2D6HTR1AOPRM1 | |
| Tetrahydrozoline SCHEMBL1512892 | 0.88 | ADRA1A (0.81) | ADRA1AADRA2ACYP2D6HTR1AOPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122075696-A | Application of MSR1 inhibitor in preparation of anti-tumor immunopotentiator | — | 2026-05-26 | — | — | CN | disclosed |
| EP-2376074-B1 | METHOD FOR IMPROVED BIOACTIVATION OF MEDICATIONS | DRITTE PATENTPORTFOLIO BETEILI (DE) | 2019-03-13 | — | — | EP | disclosed |
| CN-105008128-A | OXYGEN-ABSORBING MULTILAYER BODY, OXYGEN-ABSORBING CONTAINER, OXYGEN-ABSORBING AIRTIGHT CONTAINER, OXYGEN-ABSORBING PUSH-THROUGH PACK, AND STORAGE METHOD USING SAME | MITSUBISHI GAS CHEMICAL CO | 2015-10-28 | — | — | CN | disclosed |
| US-20120077876-A1 | Method For Improved Bioactivation Of Pharmaceuticals | DRITTE PATENTPORTFOLIO BETEILIGUNGSGESELLSCHAFT MBH & CO. KG (DE) | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077876-A1 | Method For Improved Bioactivation Of Pharmaceuticals | CYP2B6, CYP1A2, CYP2D6 | ADRA1A 226/4885ADRA2A 331/4885ADRA1D 571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.